Recent studies have reported that HMGB1 levels are enhanced in NAFLD in both animal models and a clinical setting in humans and that inhibiting HMGB1 leads to a remarkable decrease in inflammatory responses in NAFLD (Li et al., 2011; Montes et al., 2015). The gene discussed is HMGB1; the disease is metabolic dysfunction-associated steatotic liver disease.